The clinical significance of long non-coding RNA ANRIL level in diabetic retinopathy.


Journal

Acta diabetologica
ISSN: 1432-5233
Titre abrégé: Acta Diabetol
Pays: Germany
ID NLM: 9200299

Informations de publication

Date de publication:
Apr 2020
Historique:
received: 02 06 2019
accepted: 22 10 2019
pubmed: 7 11 2019
medline: 1 7 2020
entrez: 7 11 2019
Statut: ppublish

Résumé

To analyse the expression of lncRNA-ANRIL and other related factors in different human body fluids, explore the clinical significance of ANRIL and validate whether ANRIL is interrelated with the renin-angiotensin system and NF-κB signalling pathway. Ninety-one patients were included in this cross-sectional study and were divided into the NDM group (20 patients), DM group (25 patients), NPDR group (21 patients) and PDR group (25 patients). Basic information and samples of serum, aqueous fluid and vitreous fluid were collected before vitrectomy or intravitreal injection. The transcription and levels of ANRIL and other related factors were detected by RT-PCR and ELISA. Statistical Package for Social Sciences software was used for statistical analysis. ANRIL expression varied among different groups and body fluids. There was no difference in ANRIL expression between the NDM and DM groups, but the level of ANRIL was significantly lower in the DM group than in the NPDR and PDR group. In vitreous fluid, ANRIL expression was positively correlated with Ang II, p65 and VEGF expression in the PDR group. The expression of ANRIL in serum was not significantly correlated with age or the random blood sugar but was positively correlated with diabetic duration and HbAc1 level. Levels of lncRNA-ANRIL are higher in DR patient and correlated with the progression of DR that may be used as an indicator to predict the development of DR. The activation of the RAS and the NF-κB pathway may be closely related to the upregulation of ANRIL. Clinical trial number ChiCTR1800017500. Registry Chinese Clinical Trial Registry.

Identifiants

pubmed: 31691869
doi: 10.1007/s00592-019-01442-2
pii: 10.1007/s00592-019-01442-2
pmc: PMC7093365
doi:

Substances chimiques

CDKN2B antisense RNA, human 0
NF-kappa B 0
RNA, Long Noncoding 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

409-418

Subventions

Organisme : National Natural Science Foundation of China
ID : No. 81800804
Organisme : Clinical Research Startup Program of Southern Medical University
ID : LC2016YM017

Références

Nature. 2008 Jan 10;451(7175):202-6
pubmed: 18185590
Oncotarget. 2014 Apr 30;5(8):2276-92
pubmed: 24810364
Cancer Res. 2007 Apr 15;67(8):3963-9
pubmed: 17440112
Clin Ophthalmol. 2017 Jan 21;11:193-200
pubmed: 28176934
Front Genet. 2015 Apr 23;6:145
pubmed: 25954300
EBioMedicine. 2017 Aug;22:181-190
pubmed: 28774737
Invest Ophthalmol Vis Sci. 2017 Jan 1;58(1):470-480
pubmed: 28122089
FASEB J. 2011 Feb;25(2):444-8
pubmed: 20956613
Curr Top Microbiol Immunol. 2016;394:29-39
pubmed: 26220772
Arch Ophthalmol. 1960 Apr;63:715-20
pubmed: 14436800
Oxid Med Cell Longev. 2016;2016:3528274
pubmed: 27143993
Eur J Epidemiol. 2018 Feb;33(2):141-156
pubmed: 29204902
Invest Ophthalmol Vis Sci. 2014 Feb 18;55(2):941-51
pubmed: 24436191
Nat Struct Mol Biol. 2012 Jun 03;19(7):664-70
pubmed: 22659877
Am J Ophthalmol. 2013 Feb;155(2):342-353.e5
pubmed: 23111177
Int J Mol Sci. 2018 Mar 22;19(4):
pubmed: 29565290
Oncotarget. 2017 Mar 7;8(10):17347-17359
pubmed: 28060742
J Endocrinol Invest. 2017 Sep;40(9):925-935
pubmed: 28357783
RNA Biol. 2016;13(1):98-108
pubmed: 26618242

Auteurs

ShuZe Chen (S)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

HuiMin Zhong (H)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

Yan Wang (Y)

Department of Ophthalmology, Shenzhen Hospital, Southern Medical University, Guangzhou, Guangdong, China.

ZiHong Wang (Z)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

XiaoQian Liang (X)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

SiQi Li (S)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

ZhenHao Li (Z)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

ZhengTong Yu (Z)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.

LiYing Li (L)

Department of Ophthalmology, Shenzhen Hospital, Southern Medical University, Guangzhou, Guangdong, China.

GuoGuo Yi (G)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. ygigi2004@163.com.

Min Fu (M)

Department of Ophthalmology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. min_fu1212@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH